American Journal of Clinical Dermatology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Cutaneous Leishmaniasis: A 2022 Updated Narrative Review into Diagnosis and Management Developments
AbstractThis review is an update of an earlier narrative review published in 2015 on developments in the clinical management of cutaneous leishmaniasis (CL) including diagnosis, treatment, prevention and control measurements. CL is a vector-borne infection caused by the protozoan parasiteLeishmania. The vector is the female sandfly. Globally, CL affects 12 million cases and annually 2 million new cases occur. CL is endemic in almost 100 countries and the total risk population is approximately 350 million people. WHO lists CL an emerging and uncontrolled disease and a neglected tropical disease. Local experience-based evide...
Source: American Journal of Clinical Dermatology - September 14, 2022 Category: Dermatology Source Type: research

Drug Survival of Oral Retinoids in Hidradenitis Suppurativa: A Real-Life Cohort Study
ConclusionComparable drug survival rates at 12 months for isotretinoin and acitretin were found. HS patients with widespread comedones and the scarring folliculitis phenotype could benefit from treatment with isotretinoin or acitretin, respectively. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - September 7, 2022 Category: Dermatology Source Type: research

Treatment of Hyperhidrosis: An Update
AbstractHyperhidrosis is a dermatosis presenting as pathologically excessive focal or generalized sweating. The stigmatizing nature of hyperhidrosis may cause patients to feel embarrassment and apprehension about their symptoms and experience a significant decrease in well-being. Severe cases of hyperhidrosis can also increase the risk of developing psychiatric and somatic comorbidities. Conventional non-surgical treatments of hyperhidrosis include aluminum salts, iontophoresis, botulinum toxin injections, and oral glycopyrronium. In recent years, new topical anticholinergic medications and devices have emerged that may im...
Source: American Journal of Clinical Dermatology - September 1, 2022 Category: Dermatology Source Type: research

What ’s New in Topicals for Atopic Dermatitis?
AbstractAtopic dermatitis (AD) is a chronic inflammatory skin condition that can have tremendous impact on quality of life for affected children and adults. First-line therapy for acute management of AD includes topical therapies such as corticosteroids, calcineurin inhibitors, and, more recently, the phosphodiesterase inhibitor crisaborole. Topical agents have remained the mainstay therapy for decades; however, there has been a longstanding need for topical therapies with high efficacy and low risk of adverse effects with long-term use. Given the ongoing advances in understanding the pathogenesis of AD, there are novel ta...
Source: American Journal of Clinical Dermatology - September 1, 2022 Category: Dermatology Source Type: research

New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review
ConclusionsBoth new-onset psoriasis and psoriasis flares were reported as cutaneous adverse events following COVID-19 vaccination. Psoriatic patients may require regular follow-up before and after COVID-19 vaccination.Trial RegistrationReview registration number PROSPERO database: CRD42022304157. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - September 1, 2022 Category: Dermatology Source Type: research

Alcohol and Psoriasis for the Dermatologist: Know, Screen, Intervene
AbstractPsoriasis patients are at increased risk of harmful alcohol use and alcohol dependency with many deleterious effects. Increasing alcohol use is associated with worsening psoriasis severity, is a risk factor for poor response to systemic treatments and may impact on comorbidities such as psoriatic arthritis, cardiovascular disease, cancer and liver disease. Harmful alcohol use and alcohol dependency can be defined by the updated ICD-11 coding system and screening can be completed using many tools including the Cut down, Annoyed, Guilty, Eye-Opener (CAGE), Alcohol Use Disorders Identification Test (AUDIT) and Michiga...
Source: American Journal of Clinical Dermatology - August 23, 2022 Category: Dermatology Source Type: research

Drug Survival of Interleukin (IL) ‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study
ConclusionThe cumulative probability of drug survival of both IL-17 and IL-23 inhibitors was higher than 75% at 24 months, with risankizumab and guselkumab demonstrating to have overall cumulative probabilities ≥ 90%. Biological agent chosen, prior exposure to biologic agents, higher baseline BMI and PASI values, and absence of family history of psoriasis were identified as predictors for drug discontinuati on. Risankizumab, guselkumab, and ixekizumab were less likely to be discontinued than secukinumab. (Source: American Journal of Clinical Dermatology)
Source: American Journal of Clinical Dermatology - August 17, 2022 Category: Dermatology Source Type: research

Management of Coexisting Bullous Pemphigoid and Psoriasis: A Review
AbstractPsoriasis in an immune-mediated inflammatory disease and is associated with increased risk of various comorbidities, especially autoimmune bullous diseases. However, the optimal management of coexisting psoriasis and bullous pemphigoid (BP) is not known. A systematic search revealed 64 articles, including 84 patients with such cases. For those with mild BP activity and clear triggers, discontinuation of culprit agents and using topical corticosteroid was the most common treatment. Systemic corticosteroids and methotrexate were most widely used for moderate to severe diseases, but flare up of BP and psoriasis was co...
Source: American Journal of Clinical Dermatology - August 14, 2022 Category: Dermatology Source Type: research